Structural Biology of Ubiquitination

From Mechanisms to Interventions

Häftad, Engelska, 2026

2 289 kr

Kommande

Structural Biology of Ubiquitination: From Mechanisms to Interventions provides an in-depth exploration of the structural and biophysical principles governing ubiquitination and their implications in diseases such as cancer and neurodegeneration. The book seamlessly integrates experimental insights with advanced computational methods, including AI-driven drug discovery, molecular modeling, and biophysical simulations, offering a comprehensive toolkit for researchers and clinicians. By bridging fundamental science with translational applications, the book empowers readers to design targeted therapeutics, understand disease mechanisms at the molecular level, and accelerate progress toward personalized medicine.

Provides structural insights into ubiquitination pathways and their roles in diseases such as cancer and neurodegeneration
Utilizes computational and AI-driven approaches to advance drug discovery
Highlights the therapeutic relevance of the ubiquitin-proteasome system
Bridges experimental and computational research to support precision medicine

Produktinformation

Utgivningsdatum2026-11-01
Mått191 x 235 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor350
FörlagElsevier Science
ISBN9780443449741

Tillhör följande kategorier

Tillämpad fysik inom Naturvetenskap och teknik
Biokemi inom Naturvetenskap och teknik
Biologi inom Naturvetenskap och teknik

Navaneet Chaturvedi is an assistant professor at the Amity Institute of Biotechnology, Amity University, Noida, India. He has built a solid foundation and essential skills for a research-intensive role. With extensive experience, Dr. Chaturvedi is eager to contribute to the vibrant research community. His work spans institutions worldwide, including Tel Aviv University, IIT BHU, University of Information Science & Tech North Macedonia, University of Leicester, and PharmCADD in South Korea, enabling collaboration with multidisciplinary teams and fostering innovation. His expertise includes molecular dynamics simulation, molecular docking, free energy calculations, machine learning, protein folding, and computer-aided drug design. Dr. Chaturvedi has a growing portfolio of research and review articles and book chapters published in leading international journals and publishers. Vijay Kumar, PhD, is an assistant professor at Amity University. He earned his PhD in Biophysics from AIIMS, New Delhi, and completed a postdoctoral fellowship at UMass Medical School, focusing on folding and aggregation of proteins such as SOD1 and TDP-43 implicated in motor neuron disease, ALS, and FTD. Returning to India, he served as Principal Investigator under the DST-SERB Young Scientist Scheme at Jamia Millia Islamia. His current research centers on protein folding, misfolding, and aggregation, and the role of toxic RNA species in neurodegenerative diseases. He is a member of the Protein Society, Indian Biophysical Society, Indian Academy of Neurosciences, and the International Society for Neurochemistry. He has held fellowships from CSIR and a DAAD fellowship in Germany.

1. Introduction to Ubiquitination: Mechanisms, enzymes (E1, E2, E3), and biological significance2. Structural level of Ubiquitination through the eyes of Cryo-EM, X-ray crystallography, and NMR3. Structural biology of Ubiquitin ligases4. Computational Biophysics in Ubiquitination Studies5. Dysregulation of Ubiquitination in Cancer: Molecular mechanisms and oncogenic pathways6. Deubiquitinases (DUBs) as Cancer Regulators: Structural and Computational Insights for targeted therapy7. Dysregulation of Ubiquitination in Neurodegeneration: Molecular mechanisms and neurodegenerative pathways8. Deubiquitinases (DUBs) in Amyotrophic Lateral Sclerosis (ALS): Mechanisms and therapeutic interventions9. AI and Machine Learning in Ubiquitination and Drug Discovery10. PROTACs and Targeted Protein Degradation Strategies in Ubiquitination-linked Disease Therapy11. Challenges and Future Perspectives in Ubiquitination Research12. Translational Research and Clinical Trials in Ubiquitination-Targeted Therapy